Company Overview:

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

[stock_market_chart symbol=”MYM.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$0.12
Market Capitalization (in Millions)$15.09
Last Quarter (Share Data)2/28/2019
Shares Outstanding (in Millions)125.72
Options (in Millions)9.11
Warrants (in Millions)14.09
Fully Diluted (in Millions)148.91
<th<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td
<!DOCTYPEhtml><metaname="google"content="notranslate"><metaname="viewport"content="target-densitydpi=device-dpi,user-scalable=1,minimum-scale=1,maximum-scale=2.5,initial-scale=1,width=device-width"><metahttp-equiv="X-UA-Compatible"content="IE=edge;"><metaname="referrer"content="origin">MYM</td><td class="column-11">Nutraceuticals</td><td class="column-12">-</td><td class="column-13">Google</td><td class="column-14">Drive<linkrel="shortcuticon"href="//ssl.gstatic.com/docs/spreadsheets/favicon3.ico"><linkhref='/static/spreadsheets2/client/css/2968578022-waffle_k_ltr.css'type='text/css'rel='stylesheet'nonce="Fw9E7jRvoxHul7G8hNScZg"><styletype="text/css"nonce="Fw9E7jRvoxHul7G8hNScZg">
html{overflow:visible;}
#sheets-viewport{overflow:auto;}
#sheets-viewport.widget-viewport{overflow:hidden;}
.grid-container{overflow:visible;background:white;}
.grid-table-container{overflow:visible;}
#top-bar{
margin:0;
overflow:hidden;
}
#top-bar{
border-bottom:1pxsolid#ccc;
padding:6px6px0;
}
#doc-title{padding-bottom:5px;}
#doc-title.name{font-size:15px;}
#sheet-menu{
font-size:13px;
margin:6px00;
padding:005px;
}
#sheet-menuli{
display:inline;
list-style-type:none;
margin:0;
padding:5px8px;
}
#sheet-menuli.active{
background-color:#fff;
font-weight:bold;
border:1pxsolid#999;
}
#top-bar#sheet-menuli.active{
border-bottom:0;
}
#sheet-menua,#sheet-menua:visited{color:#07c;}
#footer{
background:#f0f0f0;
border-top:1px#cccsolid;
border-bottom:1px#cccsolid;
font-size:13;
padding:10px10px;
}
.dash{
padding:06px;
}
.ritz.wafflea{color:inherit;}.ritz.waffle.s1{background-color:#ffffff;text-align:center;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}.ritz.waffle.s0{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">
varactiveSheetId;
functionswitchToSheet(id){
if(document.getElementById('sheet-menu')){
document.getElementById('sheet-button-'+activeSheetId)
.className='';
document.getElementById('sheet-button-'+id).className='active';
}
document.getElementById(activeSheetId).style.display='none';
document.getElementById(id).style.display='';
activeSheetId=id;
//posObjs()isdefinedinembeddedObjectJs(seeEmbeddedObjectHtmlBuilder.java)
posObjs();
returnfalse;
}
functioninit(){
varoptPageSwitcher;
functionresize(){
varoptMobileWebHeader=document.getElementById('docs-ml-header-id');
varoptTopBar=document.getElementById('top-bar');
varoptFooter=document.getElementById('footer');
varsheetsViewport=document.getElementById('sheets-viewport');
if(optMobileWebHeader){
sheetsViewport.style.marginTop=optMobileWebHeader.offsetHeight+
(optTopBar?optTopBar.offsetHeight:0)+'px';
}
varadjustedHeight=window.innerHeight-
(optTopBar?optTopBar.offsetHeight:0)-
(optFooter?optFooter.offsetHeight:0);
varadjustedWidth=window.innerWidth;
sheetsViewport.style.width=(adjustedWidth+'px');
sheetsViewport.style.height=(adjustedHeight+'px');
if(optPageSwitcher){
optPageSwitcher.resize(adjustedWidth,adjustedHeight);
}
}
resize();
window.onresize=resize;
varcurrentUrl=window.location.href;
varnewUrl=currentUrl.replace('?sle=true&','?');
newUrl=newUrl.replace('?sle=true','');
newUrl=newUrl.replace('&sle=true&','&');
newUrl=newUrl.replace('&sle=true','');
window.history.replaceState(null,'',newUrl);
}
<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">_docs_flag_initialData={"docs-mwid":false,"docs-smheo":false,"info_params":{"includes_info_params":true},"ilcm":{"eui":"ADFN-ctoHzWx9j47QMwHvC0oA13I7GJCkxvKJTCVQTTUU5ZYqxEV1bNi0EwGJn7mYxWxdHBMXlSK","je":1,"sstu":1623926851831000,"si":"CNSQlPm-nvECFVaGqwcd6RgGyw","gsc":0,"ei":[5707711,5703186,5731094,5708862,5705301,5714628,5707197,5728103,5737700,5700019,5713152,5723284,5717118,5704063,5711808,5710677,5709709,5737898,5733710,5714961,5715515,5709892,5707385,5708480,5709381,5707047,5715399,5715637,5719170,5706133,5714843,5716141,5738168,5703913,5723871,5712352,5702767,5707943,5702912,5710637,5711708,5711850,5720479,5737401,5720568,5725052,5722301,5712033,5704621,5704883,5700559,5721815,5719212,5707609,5710645,5717949,5713207,5711471,5739056,5701903,5724085,5702135,5708574,5721004,5708886,5733973,5706601,5733570,5737254,5713227,5728335,5732963,5725300,5725338,5720788,5713681,5705777,5714796,5712469,5716149,5700884,5714326,5724916,5709476,5711765,5713195,5728567,5716028,5704144,5720487,5735134,5715364,5707986,5720483,5710746,5706169,5711550,5712929,5720925,5711099,5721764,5704641,5711155,5720595,5728475,5702849,5719535,5713597,5714322,5720516,5717161,5713223,5707204,5705040,5701034,5707856,5711012,5703837,5730285,5713049,5712909,5735509,5714674,5702445,5714967,5734352,5713605,5710476,5711957,5720714,5703591,5727257,5724896,5708974,5706933,5710938,5724533,5703027,5729546,5712905,5711297,5722346,5712525,5710933,5713542,5728515,5707445,5710542,5715641,5702785,5712298,5708870,5719527,5714330,5735281,5728083,5711685,5722409,5715222,5727901,5731530,5719462,5709661,5727063,5721344,13702623,5706069,5710893,5712211,5731412,5712477,5703839,5711826,5717070,5713191,5730290,5727853,5716457,5702936,5705223,5706270,5731783,5711524,5713554,5707819,5703022,5703815,5703182,5719482,5712373,5711769,5725742,5737153,5734571,5705493,5720060,5700422,5721012,5719531,5714839,5726110,5705581,5712913,5709357,5735670,5722370,5719651,5711230,5704581,5728945,5711889,5715246,5725511,5727042,5712635,5707425,5706523,5721361,5719502,5700446,5728807,5722189,5719418,5706661,5734994,5722567,5714445,5710692,5736924,5714550,5713333,5701650,5726190,5703762,5721307,5726595,5714310,5707137,5712473,5715824,5709447,5730867,5705649,5716416,5703259,5738433,5735806,5709085,5713211,5701594,5723679,5729072,5706007,5706751,5729206,5716145,5713657,5707657,5735630,5723365,5727624],"crc":0,"cvi":[]},"drive_url":"//drive.google.com?usp\u003dsheets_web","docs-ehr":true,"docs-sup":"/spreadsheets"};_docs_flag_cek='';if(window['DOCS_timing']){DOCS_timing['ifdld']=newDate().getTime();}<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">document.addEventListener('DOMContentLoaded',init);<bodyclass="docs-gm"><divid="top-bar"><divid="doc-title"><spanclass="name">MYMNutraceuticals:KeyShareInfo2<divid="sheets-viewport"><divid="1294638516"style="display:none;position:relative;"dir="ltr"><divclass="ritzgrid-container"dir="ltr"><tableclass="waffle"cellspacing="0"cellpadding="0">
class="row-headerfreezebar-origin-ltrheader-shimrow-header-shim"><thid="1294638516C0"style="width:191px;"class="header-shim"><thid="1294638516C1"style="width:100px;"class="header-shim">
style="height:20px"><thid="1294638516R0"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">1<tdclass="s0">EnterpriseValue(inMIllions)class="s1">$14.24
style="height:20px"><thid="1294638516R1"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">2<tdclass="s0">TTMRevenueclass="s1">$1.78
style="height:20px"><thid="1294638516R2"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">3<tdclass="s0">TTMGrowthMargin%class="s1">65.27%
style="height:20px"><thid="1294638516R3"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">4<tdclass="s0">TTMOperatingExpensesclass="s1">$16.26
style="height:20px"><thid="1294638516R4"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">5<tdclass="s0">TTMOCFclass="s1">-$8.63
style="height:20px"><thid="1294638516R5"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">6<tdclass="s0">P/STTMclass="s1">8.47
style="height:20px"><thid="1294638516R6"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">7<tdclass="s0">P/S(LastQuarterRunRate)class="s1">#DIV/0!
<divid="footer">Publishedby<atarget="_blank"title="LearnmoreaboutGoogleSheets"href="https://docs.google.com/spreadsheets/?usp=sheets_web">GoogleSheets<spanclass="dash">–<ahref="https://docs.google.com/abuse?id=AKkXjoxJPPdT2XZQJ9j1xk56iAncfZHswcfOdDDCv4pDyGeDPRtPlG4JrPFvJQk1Nj2IigePBFtgXVU3uPjrW-o:0">ReportAbuse<spanclass="dash">–Updatedautomaticallyevery5minutes
<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">activeSheetId='1294638516';switchToSheet('1294638516');

Key Balance Sheet Information (in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.11$0.32$0.55$0.27$2.04$10.11$6.63$1.74$0.91$1.72
Biological Assets
Inventory$0.04$0.03$0.06$0.10$1.06$1.11$0.81$0.77
Total Assets$0.13$0.49$1.77$2.12$6.62$20.45$21.11$22.50$20.27$20.04
Net Tangible Assets$0.12$0.48$0.87$1.05$4.99$16.89$17.22$18.61$17.17$16.94
Intangibles/Goodwill$0.00$0.00$0.90$1.07$1.63$3.56$3.89$3.89$3.10$3.10
Total Liabilities$0.42$0.35$0.26$0.25$0.57$1.28$1.20$2.95$1.16$0.87

Key Operating Items (Quarterly in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.14$0.28$0.40$0.48$1.78
Change in Fair Value of Biologial Assets
Gross Margin$0.06$0.19$0.25$0.40$1.16
Marketing and Sales
Investor Relations$0.00$0.01$0.02$0.12$0.32$0.58$1.570.230.34$0.43
Total Operating Expenses$0.04$0.10$0.88$0.79$1.25$2.20$6.782.732.78$3.98
Operating Cash Flow (Quarterly)-$0.03-$0.21-$0.43-$1.09-$1.60-$3.75-4.08-$0.80
Investing Cash Flow (Quarterly)-$0.07$0.02-$1.70-$2.70-$1.88-1.61-$0.03
Financing Cash Flow (Quarterly)$0.00$0.48$0.64$4.56$12.36$2.154.87$1.64

Listing Statement

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

First Majestic Posts Record Quarterly Silver Production In Q3

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings